Found 12 clinical trials
Novel Combination Therapy for Osteoporosis in Men (Osteo-Men)
Osteoporotic fractures are a key health problem in older men. Although there are drugs approved to treat osteoporosis in men [bisphosphonates, denosumab, and teriparatide (TPTD) or PTH(1-34)], there is a lack of knowledge on how to use them effectively. TPTD is a potent bone anabolic drug, meaning that it builds …
- 39 views
- 26 Feb, 2022
- 1 location
A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis
The purpose of this study is to evaluate the effect of alendronate sodium vitamin D3 tablets compared with placebo on the improvement of joint structure and joint pain in participants with knee
- 0 views
- 01 May, 2022
- 3 locations
Phase IV Clinical Trial to Evaluate Efficacy and Safety of MASI BONE S (Alendronate Sodium Trihydrate) in Postmenopausal Women With Osteoporosis
This study aims to prove non-inferiority of the efficacy of Masibone S (alendronate sodium trihydrate 70mg, oral solution) on the treatment of postmenopausal osteoporosis compared to the
- 0 views
- 13 Jun, 2022
- 1 location
Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
extension study will offer subjects 12-month administration of open-label alendronate (an oral bisphosphonate) 70 mg once weekly after the initial 12 month administration of romosozumab or placebo. The
- 8 views
- 17 Jun, 2022
- 1 location
The Optimal Sequential Therapy After Long Term Denosumab Treatment
This study intends to investigate whether Alendronate and Zoledronate can prevent bone mineral density loss after long-term treatment with Denosumab.
- 0 views
- 02 Nov, 2021
- 1 location
Romosozumab in Women With Chronic SCI
). Participants will receive monthly injections of romosozumab during the first 12 months of the study. During the second year, participants will take oral alendronate tablets on a weekly basis.
- 0 views
- 25 Mar, 2022
- 1 location
Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study
last denosumab dose) or weekly alendronate (6 months after last denosumab dose).
- 0 views
- 26 Dec, 2021
- 1 location
Bisphosphonates for Prevention of Post-Denosumab Bone Loss
investigator will observe participants for a second year off bisphosphonate therapy to assess duration of response. The hypothesis is that bisphosphonate therapy with alendronate or zoledronic acid
- 78 views
- 03 Mar, 2022
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
Osteoporosis affects 24.5% of women over 65 and results in fracture-related hospital admissions exceeding those of heart attacks, strokes and breast cancer combined. Current treatment options do not account for differences between age-related and estrogen deficiency related osteoporosis, because of the need for bone biopsies for determination. This study will …
- 0 views
- 25 May, 2022
- 1 location
Denosumab Sequential Therapy
Denosumab is a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis. Although denosumab has excellent effect to increase bone mass and prevent fracture in FREEDOM study with very low complications, even up to ten years, it's effect is reversible. After holding the drug, circulating denosumab …
- 0 views
- 27 Jan, 2021
- 1 location
- 1
- 2